Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Care Fraud Investigations Bedevil Pharma Industry: If You're Not Under Investigation, It's Only Because You've Recently Settled

Executive Summary

Two months ago, the Department of Justice held a splashy news conference to announce its record-breaking $2.3 billion settlement with Pfizer. The event, which included HHS Secretary Kathleen Sebelius, cast a spotlight on Pfizer's alleged off-label marketing and kickbacks to health care providers (1"The Pink Sheet," Sept. 7, 2009)
Advertisement

Related Content

Qui Tam Litigation: Peter Rost Suit Fails As Others Thrive
Pfizer Says Government Investigations Must Be Avoided, Since "There Is No Way Of Winning" Once They Start
Pharma Compliance Is Big Business; Software Vendors Offer Trove Of Tools
Cell Therapeutics Can Sue Consultant For Advice On Off-Label Reimbursement
Omnicare Settlement With DoJ Shows Power Of Nursing Homes In Driving Rxs
Seroquel Off-Label Settlement Puts Clinical Researchers In Spotlight
Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior
Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior
Lilly’s Zyprexa Off-Label Settlement: Record Fine, Routine Compliance Deal
Bristol To Pay $500 Million Civil Fine Under Tentative Deal With U.S. Attorney

Topics

Advertisement
UsernamePublicRestriction

Register

PS051672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel